Zimmer Biomet Holdings, Inc. to Issue Quarterly Dividend of $0.24 (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announced a quarterly dividend on Wednesday, December 17th. Shareholders of record on Tuesday, December 30th will be paid a dividend of 0.24 per share by the medical equipment provider on Friday, January 30th. This represents a c) annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, December 30th.

Zimmer Biomet has a payout ratio of 11.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Zimmer Biomet to earn $8.87 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 10.8%.

Zimmer Biomet Trading Up 0.7%

Shares of NYSE:ZBH opened at $91.53 on Thursday. The stock has a market cap of $18.14 billion, a PE ratio of 22.66, a P/E/G ratio of 2.39 and a beta of 0.61. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. Zimmer Biomet has a 12-month low of $85.33 and a 12-month high of $114.44. The business has a 50 day moving average of $95.21 and a 200-day moving average of $96.70.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The business had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same period last year, the firm posted $1.74 EPS. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ZBH shares. Robert W. Baird reissued a “neutral” rating and issued a $100.00 target price (down previously from $117.00) on shares of Zimmer Biomet in a research report on Tuesday. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $100.00 price objective (down previously from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Canaccord Genuity Group decreased their target price on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a research report on Monday, November 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Finally, BTIG Research reduced their price target on Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average price target of $107.50.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.